KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Operating Expenses (2018 - 2025)

Castle Biosciences' Operating Expenses history spans 7 years, with the latest figure at $90.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 10.43% year-over-year to $90.8 million; the TTM value through Dec 2025 reached $387.0 million, up 19.68%, while the annual FY2025 figure was $387.0 million, 19.68% up from the prior year.
  • Operating Expenses for Q4 2025 was $90.8 million at Castle Biosciences, up from $89.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $115.9 million in Q1 2025 and bottomed at $24.1 million in Q1 2021.
  • The 5-year median for Operating Expenses is $71.5 million (2023), against an average of $67.0 million.
  • The largest annual shift saw Operating Expenses surged 139.07% in 2021 before it rose 6.64% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $40.2 million in 2021, then skyrocketed by 52.13% to $61.2 million in 2022, then rose by 17.34% to $71.8 million in 2023, then grew by 14.6% to $82.3 million in 2024, then rose by 10.43% to $90.8 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Operating Expenses are $90.8 million (Q4 2025), $89.8 million (Q3 2025), and $90.4 million (Q2 2025).